Clinical and laboratory features and subsequent events in 107 patients with MDS-RS, stratified by the presence or absence of the SF3B1 mutation
| Variable . | All patients with MDS-RS (n = 107) . | MDS-RS patients with the SF3B1 mutation (n = 53) . | MDS-RS patients without the SF3B1 mutation (n = 54) . | P . |
|---|---|---|---|---|
| Median age, y (range) | 71 (17-89) | 74 (50-89) | 68 (17-83) | .20 |
| Males, n (%) | 76 (71) | 34 (64) | 42 (78) | .12 |
| Hemoglobin, g/dL, median (range) | 9.3 (5.8-15.7) | 9.2 (5.8-12.3) | 8.9 (6.1-15.7) | .33 |
| WBC, × 109/L, median (range) | 4.5 (1.2-35.2) | 4.5 (1.2-11.7) | 3.8 (1.2-35.2) | .22 |
| ANC, × 109 /L, median (range) | 2.2 (0.8-32) | 3.2 (0.8-9.2) | 1.6 (0.8-32) | .4 |
| Platelets, × 109 /L, median (range) | 179 (6-585) | 232 (14-585) | 108 (6-484) | < .0001 |
| PB blast, %, median (range) | 0 (0-8) | 1 (0-1) | 0 (0-8) | .12 |
| BM blast, %, median (range) | 1 (0-12) | 1 (0-9) | 1 (0-12) | .01 |
| BM cellularity, %, median (range) | 70 (30-100) | 70 (30-95) | 70 (30-100) | .68 |
| WHO histologic categories, n (%) | < .0001 | |||
| RARS | 48 (49) | 35 (66) | 13 (24) | |
| RCMD | 43 (40) | 16 (30) | 27 (50) | |
| MDS-U | 0 (0) | 0 (0) | 0 (0) | |
| RAEB-1 | 11 (10) | 2 (4) | 9 (17) | |
| RAEB-2 | 5 (5) | 0 (0) | 5 (9) | |
| Mutational analysis, n (%) | .10 | |||
| IDH1 | 1 (1) | 0 (0) | 1 (2) | |
| IDH2 | 6 (6) | 1 (2) | 5 (9) | |
| JAK2V617F | 5 (5) | 2 (4) | 3 (6) | |
| MPL | 0 (0) | 0 (0) | 0 (0) | |
| IPSS risk categories, n (%) | < .0001 | |||
| Low | 7 (7) | 5 (9) | 2 (4) | |
| Intermediate-1 | 80 (75) | 48 (90) | 32 (59) | |
| Intermediate-2 | 19 (18) | 0 (0) | 19 (35) | |
| High | 1 (1) | 0 (0) | 1 (2) | |
| IPSS-R risk categories, n (%) | .0001 | |||
| Very good | 20 (19) | 13 (34) | 7 (13) | |
| Good | 57 (53) | 36 (68) | 21 (39) | |
| Intermediate | 10 (9) | 2 (4) | 8 (15) | |
| Poor | 3 (3) | 1 (2) | 2 (4) | |
| Very poor | 17 (16) | 1 (2) | 16 (30) | |
| Transfusion-dependent, n (%) | 29 (27) | 9 (17) | 20 (37) | .03 |
| Leukemic transformations, n (%) | 11 (10) | 1 (2) | 10 (18) | .004 |
| Deaths, n (%) | 75 (70) | 32 (60) | 43 (80) | .02 |
| Variable . | All patients with MDS-RS (n = 107) . | MDS-RS patients with the SF3B1 mutation (n = 53) . | MDS-RS patients without the SF3B1 mutation (n = 54) . | P . |
|---|---|---|---|---|
| Median age, y (range) | 71 (17-89) | 74 (50-89) | 68 (17-83) | .20 |
| Males, n (%) | 76 (71) | 34 (64) | 42 (78) | .12 |
| Hemoglobin, g/dL, median (range) | 9.3 (5.8-15.7) | 9.2 (5.8-12.3) | 8.9 (6.1-15.7) | .33 |
| WBC, × 109/L, median (range) | 4.5 (1.2-35.2) | 4.5 (1.2-11.7) | 3.8 (1.2-35.2) | .22 |
| ANC, × 109 /L, median (range) | 2.2 (0.8-32) | 3.2 (0.8-9.2) | 1.6 (0.8-32) | .4 |
| Platelets, × 109 /L, median (range) | 179 (6-585) | 232 (14-585) | 108 (6-484) | < .0001 |
| PB blast, %, median (range) | 0 (0-8) | 1 (0-1) | 0 (0-8) | .12 |
| BM blast, %, median (range) | 1 (0-12) | 1 (0-9) | 1 (0-12) | .01 |
| BM cellularity, %, median (range) | 70 (30-100) | 70 (30-95) | 70 (30-100) | .68 |
| WHO histologic categories, n (%) | < .0001 | |||
| RARS | 48 (49) | 35 (66) | 13 (24) | |
| RCMD | 43 (40) | 16 (30) | 27 (50) | |
| MDS-U | 0 (0) | 0 (0) | 0 (0) | |
| RAEB-1 | 11 (10) | 2 (4) | 9 (17) | |
| RAEB-2 | 5 (5) | 0 (0) | 5 (9) | |
| Mutational analysis, n (%) | .10 | |||
| IDH1 | 1 (1) | 0 (0) | 1 (2) | |
| IDH2 | 6 (6) | 1 (2) | 5 (9) | |
| JAK2V617F | 5 (5) | 2 (4) | 3 (6) | |
| MPL | 0 (0) | 0 (0) | 0 (0) | |
| IPSS risk categories, n (%) | < .0001 | |||
| Low | 7 (7) | 5 (9) | 2 (4) | |
| Intermediate-1 | 80 (75) | 48 (90) | 32 (59) | |
| Intermediate-2 | 19 (18) | 0 (0) | 19 (35) | |
| High | 1 (1) | 0 (0) | 1 (2) | |
| IPSS-R risk categories, n (%) | .0001 | |||
| Very good | 20 (19) | 13 (34) | 7 (13) | |
| Good | 57 (53) | 36 (68) | 21 (39) | |
| Intermediate | 10 (9) | 2 (4) | 8 (15) | |
| Poor | 3 (3) | 1 (2) | 2 (4) | |
| Very poor | 17 (16) | 1 (2) | 16 (30) | |
| Transfusion-dependent, n (%) | 29 (27) | 9 (17) | 20 (37) | .03 |
| Leukemic transformations, n (%) | 11 (10) | 1 (2) | 10 (18) | .004 |
| Deaths, n (%) | 75 (70) | 32 (60) | 43 (80) | .02 |
SF3B1 indicates splicing factor 3B, subunit 1; WBC, white blood cell count; ANC, absolute neutrophil count; PB, peripheral blood; IDH, isocitrate dehydrogenase; WHO, World Health Organization; and MDS-U, myelodysplastic syndrome unclassifiable.